The management of localized prostate cancer continues to be an area of tremendous controversy. In 1 of the only clinical trials supporting an aggressive approach, an overall survival benefit for radical prostatectomy versus watchful waiting was limited to men aged <65 years at diagnosis and could be demonstrated only after 10 years of follow-up.
investigative group reported that 54% of low-risk patients in this population with Charlson scores 3 were treated aggressively (radical prostatectomy, radiation therapy, or brachytherapy). 12 Similar results were reported from studies that used very large, national samples of men. 13, 14 There also is a growing body of evidence to suggest that treatment itself can increase noncancer mortality among patients with pre-existing comorbid conditions. For example, androgen-deprivation therapy has been associated with cardiovascular disease mortality among men with prevalent cardiovascular disease. 15 Which factors might account for the failure to consider life expectancy in decisions about treatment for localized prostate cancer? There may be concerns about the ability to accurately assess life expectancy. In a Canadian survey study, 191 urologists and radiation oncologists were asked to estimate the life expectancy of patients in clinical scenarios with various patient ages and comorbidities. 16 Life-expectancy estimates were within 3 years of the true value (based on Markov model projections) in only 67% of responses. In another Canadian study, Walz et al reported only ''moderate ability'' on the part of 19 clinicians and staff to predict 10-year life expectancy in 50 patients with localized prostate cancer when provided with age, a modified Charlson score, and specific comorbidities, with a mean overall predictive accuracy based on an area under the receiver-operating curve of 0.68 (in which 0.5 represented prediction no better than chance, and 1.0 represented perfection). 17 Clearly, any prediction tools developed should at least improve accuracy beyond that based on estimates made by clinicians. However, several published nomograms based on age and comorbidities have not fared substantially better, with predictive accuracies in the range from 0.69 to 0.73. 6, 9, 18 Even the nomogram by Walz et al, 1 of the most accurate available, which has a predictive accuracy of 0.84, still is far from ideal. 8 Issues relating to the assessment of comorbidity in many of these studies may limit the accuracy of prediction tools. Comorbidity index scores, such as the Charlson, provide a tool to assist clinical researchers with adjustment for the impact of comorbidity on outcomes. However, the Charlson index is limited, in that disease severity for comorbid conditions either is not incorporated or is only crudely incorporated (eg, diabetes with or without endorgan damage). Beyond issues of the accuracy of prediction tools is their ease of use. Some published nomograms probably are too complex for use in clinical practice. Even the Charlson index, although it is implemented readily in clinical research, may be difficult to assess in patients within a busy practice setting. Another issue that may be particularly challenging to overcome is statistical illiteracy, which is exceedingly common in patients. 19 Patients have difficulty dealing with uncertainty and grasping the concept of probabilities. Thus, especially when facing a cancer diagnosis, patients may be unwilling to accept any chance of dying from their cancer, even if the actual probability of doing so is very small. The troubling implication is that, unless prediction tools are virtually perfect in their ability to discern which men will or will not die from their prostate cancer, patients may continue to choose aggressive interventions. Ongoing research into how to improve patient decisions in prostate cancer, therefore, certainly is welcomed. 20 A final point is that many of the treatment dilemmas in localized prostate cancer have their origins in inappropriate use of PSA screening. The vast majority of prostate cancer diagnoses in the current era occur after PSA screening, and the majority of those diagnoses are low-risk to intermediate-risk tumors. Yet large numbers of elderly men with comorbidities undergo PSA screening. 21 If a patient is unlikely to benefit from treatment because of age and/or comorbidity, then they should not be screened in the first place. Efforts directed at ensuring appropriate use of PSA screening should help make treatment decisions for prostate cancer easier. Although there are significant challenges, at the very least, discussions with patients about the risks and benefits of PSA screening in the context of their age and comorbidities would occur in the absence of the tremendous emotion attached to an actual cancer diagnosis.
